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Distinctive phenotype in a girl 
with Rett syndrome and a novel 
25 bp deletion mutation 
in exon 4 (c.881_905del25, nm_004992.3) 
of the MECP2 gene
Matej Katavić1, Monika Kukuruzović1, Maša Malenica1, Sara Seneca2, Ljerka Cvitanović-Šojat1
Rett syndrome is a pervasive developmental disorder with a variable clinical presentation, which is caused by point mutations or 
large deletions/duplications in the X-linked methyl-CpG-binding protein 2 (MECP2) gene. The aim is to describe variation in the 
clinical course related to the mutation identifi ed in exon 4 of the MECP2 gene. Retrospective review of data, electroencephalography 
and treatment was done in a 19-year-old girl previously diagnosed with a MECP2 gene mutation. Born after an uneventful preg-
nancy, the female patient’s growth and psychomotor development were normal, except for delayed speech. At the age of 3 years, 
tonic-clonic seizures started and at the age of 3.5 years autistic behavior was observed, followed by rapid mental deterioration, loss 
of speech and motor skills, with periods of hyperventilation. At the age of 5 years, she showed occasionally „hand-washing“ 
movements. Extensive neuro-metabolic investigation was nondiagnostic. Genetic analysis revealed a novel 25 bp deletion muta-
tion in exon 4 (c.881_905del25) of the MECP2 gene. Until now, multiple epileptic seizure types, refractory to all antiepileptic poly-
therapy and with normal video EEG background, have occurred daily. She is spastic and ataxic, but still able to walk slowly with a 
wide based gait. In this female patient, the onset of symptoms manifested much later than encountered in typical cases of 
Rett syndrome. Epilepsy with daily frequency is however drug resistant. Unexpectedly, she is still able to walk at the age of 19 
years. A genotype-phenotype correlation is suspected.
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INTRODUCTION
Rett syndrome (RTT, MIM 312750) is a severe, progressive 
neurodevelopmental disorder, now classifi ed into pervasive 
diseases. It is caused by mutations in the X-linked methyl-
CpG-binding protein 2 (MECP2) gene. The syndrome is pre-
dominantly found in females, with global prevalence of ap-
proximately one per 10 000-15 000 female newborns (1). 
Rett syndrome can be diff erentiated into two types: classi-
cal and atypical. Typical or classic Rett syndrome is charac-
terized by normal development up to the age of 7 to 18 
months. A period of developmental stagnation is followed 
by rapid vocabulary regression, stereotypic hand move-
ments, and loss of speech and acquired motor skills. In con-
trast, atypical Rett syndrome refers to a series of patients 
who do not meet all the criteria, but manifest with some 
variations in clinical presentation of the disease, character-
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ized by heterogeneity in the age of onset, severity and cli-
nical course (2). Point mutations and insertion/deletion va-
riations in the MECP2 gene (Xq28) are reported in appro-
ximately 70%-80% of classic Rett syndrome cases (3) and 
in a much lower percentage of atypical cases (4, 5). Epi-
lepsy is considered a major problem in all Rett syndrome 
patients (6).
CASE REPORT
Our patient was born after an uneventful pregnancy in a 
family with no apparent disease history, as a fourth child. 
There were no complications during the perinatal period. 
Her growth and psychomotor development were normal, 
except for delayed speech. The fi rst tonic-clonic seizure 
started at three years of age and were followed by develop-
mental and language delay and deterioration. Landau-Klef-
fner syndrome was suspected. Because of autism-like be-
havior, periods of ataxia and hyperventilation with episodes 
of breath-holding spells, eye-rolling motions and astatic 
epileptic fi ts, multiple metabolic diseases were excluded by 
numerous analyses (amino and organic acids, catalytic ac-
tivities of lysosomal enzymes). No signs of numerical or 
structural chromosomal changes were found. Electroen-
cephalographic (EEG) records during awake and sleep peri-
ods demonstrated focal and paroxysmal discharges. Mag-
netic resonance imaging (MRI) of the brain was normal and 
without signs of demyelination. Brain auditory evoked po-
tentials showed bilaterally conduction disturbances through 
the brain stem with no hearing problems. At the age of 5 
years, hand-washing movements were observed, and clini-
cal suspicion of Rett syndrome was confi rmed with identifi -
cation of a heterozygous novel 25 bp deletion mutation 
(c.881_905del25) in exon 4 of the MECP2 gene.
Multiple epileptic seizure types resistant to any drug thera-
py occurred on a daily basis. Antiepileptic drug therapy was 
started with carbamazepine, and then ethosuximide was 
added but was soon replaced with valproic acid. Car-
bamazepine was also omitted and vigabatrin was slowly 
introduced. Vigabatrin was discontinued and lamotrigine, 
shortly followed by topiramate, was introduced in therapy. 
Although the patient is still under this dual drug treatment 
to improve her EEG, she is suff ering from astatic and tonic 
seizures every day, especially in the morning. Presently, she 
has a wide based gait, spastic slow walk and major prob-
lems with sleeping. There have been occasional aggression 
incidents. 
DISCUSSION
With case description of this girl we want to emphasize how 
diff erent genotypes can have atypical phenotypes. The on-
set of symptoms began much later than usual. At the age of 
three years, she had her fi rst seizure, while seizures com-
monly occur at the age of 7 to 18 months (2, 3). In addition, 
her ability to walk at the age of 19 is still preserved (3, 5). In 
most cases of Rett syndrome, patients lose their ability to 
walk by the age of 10 years, and have lost it certainly in their 
late teens (3, 5). Continuous seizures, often seen in other 
cases of Rett syndrome (2, 6-8), but with resistance to all 
combinations of antiepileptic drug therapy, is the main 
problem in this patient. Using standard genetic analysis (2-
6), a novel deletion mutation was revealed in exon 4 of the 
MECP2 gene. The pathogenic mutations in the coding parts 
of the MECP2 exon 4 have previously been described as 
more common in Croatian girls (9).
CONCLUSION
We described a 19-year-old girl with Rett syndrome. The pa-
tient had a markedly diff erent clinical presentation of the 
illness, with epileptic seizures at daily frequency and the 
ability to walk at the age of 19 years. She was found to be 
heterozygous for a novel 25 bp deletion mutation in exon 4 
(c.881_905del25) of the MECP2 gene. To our knowledge, 
this mutation has not yet been reported. There is an impor-
tant discordance between the usual progression of the ill-
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S A Ž E T A K
Karakterističan fenotip u djevojčice s Rettovim sindromom 
i delecijom 25 bp zbog nove mutacije u 4. eksonu 
(.881_905del25, nm_004992.3) gena MECP2
M. Katavić, M. Kukuruzović, M. Malenica, S. Seneca, Lj. Cvitanović-Šojat
Rettov sindrom (RTT) pervazivni je razvojni poremećaj s različitim kliničkim slikama, a uzrokovan najčešće točkastim mutacijama ili 
delecijom/duplikacijom metil-CpG-vezanog proteina 2 (MECP2) na genu X. Cilj je opisati različitosti kliničkog tijeka bolesti koje su 
vezane za nađenu mutaciju na 4. eksonu gena MECP2. Retrospektivna analiza anamnestičkih podataka, electroencefalograma i 
liječenja kod 19-godišnje djevojke s nalazom mutacije na genu MECP2. Djevojčica je rođena nakon uredne trudnoće kao 4. dijete u 
obitelji, rast i psihomotorni razvoj su bili uredni, osim zaostatka u razvoju govora. Sa 3 godine započeli su toničko-klonički grčevi, a 
sa 3,5 godine uočava se autistično ponašanje, nakon čega je uslijedila mentalna deterioracija s prestankon govora, smetnjama 
motorike i povremenim kratkotrajnim javljanjima hiperventilacije. Sa 5 godina povremeno su se uočavali pokreti „pranja ruku“. 
 Velikim opsegom neurometaboličkih pretraga nije se našao uzrok smetnjama. Genetičkom analizom nađena je delecija 25 bp kao 
jedna od novih mutacija u 4. eksonu (c.881_905del25) gena MECP2. Uslijedili su razni oblici epileptičkih napadaja koji su bili 
 tvrdokorni na antiepileptičku terapiju, uz urednu osnovnu aktivnost na video-elektroencefalogramu. Djevojka ima povišen mišićni 
tonus, ataktičan hod i može samostalno hodati na širokoj osnovi. U ove djevojke simptomi su počeli kasnije nego u tipičnim 
slučajevima Rettovog sindroma. Epileptički napadaji su svakodnevni i tvrdokorni na terapiju, a 19-godišnja djevojka još hoda, 
a najvjerojatniji razlog je međusobna povezanost genotipa i fenotipa.
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